Bertram Stausberg Appointed As New CEO Of Bertelsmann's Printing Unit

Bertelsmann AG said Bertram Stausberg will be the new chief executive officer, or CEO, of the independent print unit being established by Bertelsmann. Stausberg will report to Bertelsmann CEO Thomas Rabe.

Prinovis's shareholders have agreed that he will simultaneously hold the position of CEO of the gravure printing company Prinovis. At present, Stausberg is managing director of Prinovis's northern German sites at Ahrensburg and Itzehoe, and the plant in Dresden.

Stausberg began his career in 1996 as assistant plant manager at Gruner Druck Itzehoe (now Prinovis Itzehoe). After that, he held successive management positions in the technical departments, and was eventually promoted to production manager. In 2006, he became head of production and engineering at Prinovis Ahrensburg. In 2009, he was appointed chief technology officer at Prinovis Nuremberg. Since 2010, he has been responsible for the Prinovis sites in Ahrensburg and Itzehoe as their managing director, and since 2011 has additionally been in charge of Prinovis Dresden's business.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT